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Drug-resistant viruses have only expanded their frequency, with vaccines offering protection to 
only a small portion of the known viruses. Exploring new ways to combat these small, infectious 
agents is a last hope. Using silver nanoparticles (AgNP), viruses were shown to reduce their 
infectious ability previous research has explored the inhibition effects of AgNP on ​HIV-1, 
Monkeypox virus, Tacaribe virus, ​and ​Hepatitis B ​(2, 3, 4, 5). In my research, I have discovered 
that the Spindle Shaped virus (SSV) is also inhibited by AgNP; this was done through examining 
and analyzing plaque assays. The method of inhibition is still unknown, but the nanoparticles 




Viruses have shown to be a threat to human lives since humanity began. Even now, the majority 
of known viruses that are a threat to humans are drug resistant. Finding new ways to combat 
these viruses involves bringing in new approaches, such as using silver nanoparticles (AgNP). In 
past research, AgNP has shown to inhibit viruses such as ​HIV-1, Monkeypox virus, Tacaribe 
virus, ​and ​Hepatitis B​ in vitro​ ​(2, 3, 4, 5). With ​HIV-1​, the AgNP seem to be binding onto the 
glycoprotein knobs on the surface of the virus, and therefore not allowing the virus to bind to 
their host (Figure 1). The antibacterial effects of silver are also well known, but when it comes to 
antivirals, the area is understudied. Showing that AgNP can inhibit the infectivity of most viruses 
is a significant step towards fighting the infectious agents. The virus used in this study, the 
Spindle Shaped Virus (SSV), thrives in acidic (pH below 4) and hot (75​o​C) environments, such 
as geothermally heated hot springs, showing that the virus has unique properties that allow it to 
survive in such extreme environments. Finding whether SSV can be inhibited by AgNP will 
show that silver may be able to inhibit the infectious ability of a wide range of viruses.  
 
  
Figure 1: a)AgNP-exposed HIV-1 virus (attached to glycoprotein knobs) 
b)HIV-1 virus not exposed to AgNP 
Source: Journal of Nanobiotechnology 2005 
 
Methods 
Silver Nanoparticle Synthesis 
The AgNP were made in Dr. Mackiewicz’s lab. Specifically, the shape of the AgNP was a 
sphere and the size was about 15 nm. They were made by reducing Ag​+​ into Ag​0​ using NaBH​4​, 
and then stabilizing the product using ligand so that it could be soluble in water. The resulting 
concentration of the spherical AgNP was 2.47*10^14 np/L.  
Testing AgNP with SSV 
Plaque assays were used to test the SSV with AgNP. The general method is shown in figure 2. 
With my process of doing plaque assays, I take 30 μl of concentrated virus stock, and I mix it 
with 270 μl of yeast-soybean based broth. From that mixture I took 30 μl and mixed it with 
another 270 μl of YS broth. I continued to do this until a 10​-5​ dilution was obtained. In order to 
incorporate the AgNP, I mixed 100 μl of AgNP with 1000 μl of concentrated virus, and I let 
them sit together for 0, 24, 72, and 96 hours. I diluted normally with that mixture. Afterwards, 
100 μl of each dilution was mixed with 0.5 mL of concentrated Sulfolobus cells. The mixture 
was filled with 5 mL of a YS/gelrite mixture and immediately plated on a petri dish. The 
dilutions were then put into a 75℃ incubator for 72 hours. Each trial was run with SSV on its 
own, as well as SSV with AgNP.  
 
Figure 2: The general method for doing plaque assays.  
 
Results 
After 0 hours of incubation, the plaque count for SSV at 10^3 on its own was too many to count 
(TMTC). For SSV + AgNP, the plaque count was 1,680,000 pfu/mL (figure 3). After 24 hours of 
incubation of the SSV and AgNP, the plaque count for SSV at 10^-4 dilution on its own was 
2.5*10^7 pfu/mL, while for SSV and AgNP, the plaque count was 2*10^6 pfu/mL at the same 
dilution. After 72 hours, the plaque count for SSV was TMTC at 10^-4 dilution, while the plaque 
count for SSV + AgNP was 2.05*10^7 pfu/mL. After 96 hours, the plaque count for SSV was 
1.3*10^7 pfu/mL at 10^4 dilution, while the plaque count for SSV + AgNP was 3.6*10^6 
pfu/mL at the same dilution (figure 4).  
 
 
Figure 3: (Left) ​Plaque assay with mixture of Wild Type and NPs at 10^3 (1,680,000 pfu/ml). 
(right) Plaque assay with Wild Type at 10^3 (TMTC) 
 
 




Knowing that there is some kind of mode of inhibition for the AgNP on SSV, we can conclude 
that AgNP can act as an antiviral on viruses that infect ​Sulfolobus​ in an acidic and hot 
environment. This repeated pattern of inhibition also shows that the AgNP is interacting with the 
virus or the cell in such a way that the virus is less infectious. Further studies could possibly 
explore the exact mode of inhibition, and specifically how the AgNP is interacting with SSV. 
Further studies can also be done with other viruses to confirm that the AgNP act as a general 
antiviral, rather than being specific to a single virus. Using different nanoparticles, ones that are 
different in size and shape could also be studied, as well as using differing concentrations. In 
conclusion, this field of study has yet to be fully explored and has a significant amount of 
potential for finding new ways of combating life-threatening viruses.  
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